{
  "variants": [
    {
      "variant": "A30P",
      "gene": "SNCA",
      "functional_evidence": {
        "description": "A30P is a Parkinson's disease (PD)-associated mutant of alpha-synuclein (SNCA) that exhibits similar PLD2 inhibition activity compared to wild-type SNCA.",
        "acmg_analysis": {
          "step_1": {
            "disease_mechanism_defined": true,
            "reason": "The paper links a-synuclein's PLD2 inhibition to disease pathogenesis via dysregulation of lipid signaling and vesicle trafficking."
          },
          "step_2": {
            "assay_applicable": true,
            "reason": "The in vitro PLD2 inhibition assay is relevant to disease pathogenesis, as PLD2 is involved in lipid signaling and vesicle trafficking."
          },
          "step_3": {
            "controls_replicates": {
              "basic_controls": false,
              "replicates": false,
              "reason": "The paper does not explicitly describe controls (e.g., empty vectors, other mutants) or replicates for the A30P variant."
            },
            "assay_validated": true,
            "reason": "PLD2 inhibition assays are standard in the field, and prior studies (cited in the paper) validate this approach."
          },
          "step_4": {
            "statistical_analysis": {
              "odds_path": false,
              "reason": "The paper does not report statistical metrics (e.g., p-values, OddsPath) for A30P."
            },
            "controls_count": {
              "total": 2,
              "reason": "The study compares A30P to wild-type SNCA and A53T but does not specify additional controls."
            },
            "strength": "BS3_supporting",
            "reason": "A30P shows no functional difference from wild-type SNCA in PLD2 inhibition, suggesting benign status. The lack of statistical analysis and limited controls reduce strength to supporting."
          }
        }
      }
    },
    {
      "variant": "A53T",
      "gene": "SNCA",
      "functional_evidence": {
        "description": "A53T is a PD-associated mutant of SNCA that exhibits increased PLD2 inhibition activity compared to wild-type SNCA.",
        "acmg_analysis": {
          "step_1": {
            "disease_mechanism_defined": true,
            "reason": "The paper links a-synuclein's PLD2 inhibition to disease pathogenesis via dysregulation of lipid signaling and vesicle trafficking."
          },
          "step_2": {
            "assay_applicable": true,
            "reason": "The in vitro PLD2 inhibition assay is relevant to disease pathogenesis, as PLD2 is involved in lipid signaling and vesicle trafficking."
          },
          "step_3": {
            "controls_replicates": {
              "basic_controls": false,
              "replicates": false,
              "reason": "The paper does not explicitly describe controls (e.g., empty vectors, other mutants) or replicates for the A53T variant."
            },
            "assay_validated": true,
            "reason": "PLD2 inhibition assays are standard in the field, and prior studies (cited in the paper) validate this approach."
          },
          "step_4": {
            "statistical_analysis": {
              "odds_path": false,
              "reason": "The paper does not report statistical metrics (e.g., p-values, OddsPath) for A53T."
            },
            "controls_count": {
              "total": 2,
              "reason": "The study compares A53T to wild-type SNCA and A30P but does not specify additional controls."
            },
            "strength": "PS3_supporting",
            "reason": "A53T shows increased PLD2 inhibition compared to wild-type SNCA, suggesting pathogenicity. The lack of statistical analysis and limited controls reduce strength to supporting."
          }
        }
      }
    }
  ]
}